KRAS and glioblastoma: KRAS mutations have been found in >95% of pancreatic ductal adenocarcinomas [50], while overexpression of Epidermal Growth Factor receptor (EGFR), which induces Ras signaling, was found in 80–90% human head and neck squamous cell carcinomas [51] and 40% of glioblastomas [52].